Literature DB >> 14991363

Acetazolamide improves neurotological abnormalities in a family with episodic ataxia type 2 (EA-2).

Hanna Harno, Timo Hirvonen, Mari A Kaunisto, Heikki Aalto, Hilla Levo, Elina Isotalo, Hannu Somer, Mikko Kallela, Aarno Palotie, Maija Wessman, Markus Färkkilä.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14991363     DOI： 10.1007/s00415-004-0299-1

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  9 in total

1.  The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.

Authors:  Karina Alviña; Kamran Khodakhah
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

2.  A case of intermittent ataxia associated with migraine headaches.

Authors:  Raymond C S Seet; Erle C H Lim
Journal:  CMAJ       Date:  2007-09-11       Impact factor: 8.262

3.  A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias.

Authors:  M Strupp; R Kalla; J Claassen; C Adrion; U Mansmann; T Klopstock; T Freilinger; H Neugebauer; R Spiegel; M Dichgans; F Lehmann-Horn; K Jurkat-Rott; T Brandt; J C Jen; K Jahn
Journal:  Neurology       Date:  2011-07-06       Impact factor: 9.910

4.  Effects of dalfampridine on attacks in patients with episodic ataxia type 2: an observational study.

Authors:  Jens Claassen; Julian Teufel; Roger Kalla; Rainer Spiegel; Michael Strupp
Journal:  J Neurol       Date:  2012-11-25       Impact factor: 4.849

Review 5.  Neuronal P/Q-type calcium channel dysfunction in inherited disorders of the CNS.

Authors:  Sanjeev Rajakulendran; Diego Kaski; Michael G Hanna
Journal:  Nat Rev Neurol       Date:  2012-01-17       Impact factor: 42.937

Review 6.  An Overview of the Current State and the Future of Ataxia Treatments.

Authors:  Kimberly Tsu Kwei; Sheng-Han Kuo
Journal:  Neurol Clin       Date:  2020-02-27       Impact factor: 3.806

Review 7.  Episodic ataxia type 2.

Authors:  Michael Strupp; Andreas Zwergal; Thomas Brandt
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

Review 8.  Therapeutic approaches in Congenital Disorders of Glycosylation (CDG) involving N-linked glycosylation: an update.

Authors:  Jan Verheijen; Shawn Tahata; Tamas Kozicz; Peter Witters; Eva Morava
Journal:  Genet Med       Date:  2019-09-19       Impact factor: 8.822

9.  Clinically severe CACNA1A alleles affect synaptic function and neurodegeneration differentially.

Authors:  Xi Luo; Jill A Rosenfeld; Shinya Yamamoto; Tamar Harel; Zhongyuan Zuo; Melissa Hall; Klaas J Wierenga; Matthew T Pastore; Dennis Bartholomew; Mauricio R Delgado; Joshua Rotenberg; Richard Alan Lewis; Lisa Emrick; Carlos A Bacino; Mohammad K Eldomery; Zeynep Coban Akdemir; Fan Xia; Yaping Yang; Seema R Lalani; Timothy Lotze; James R Lupski; Brendan Lee; Hugo J Bellen; Michael F Wangler
Journal:  PLoS Genet       Date:  2017-07-24       Impact factor: 5.917
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.